Mersana Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
- Presented additional data from XMT-1536 Phase 1 study at ESMO demonstrating compelling and consistent activity and tolerability profile in ovarian cancer
- Received FDA Fast Track Designation for XMT-1536 for patients with heavily-pretreated ovarian cancer
- Ended Q3 2020 with $271 million in cash
“During the quarter, we presented an update from the ovarian cancer cohort of the XMT-1536 Phase 1 study at ESMO, which showed continued significant anti-tumor activity in very late-stage ovarian cancer patients with response rates far exceeding standard of care and a differentiated tolerability profile. We are very encouraged by the potential of this promising therapy for people with ovarian cancer, and we look forward to providing an additional update on this program at an Analyst and Investor day around year-end,” said
Recent Highlights and Updates
- Reported positive incremental interim data from the ovarian cancer cohort of the XMT-1536 Phase 1 expansion study at the
European Society of Medical Oncology (ESMO) Virtual Congress. These data showed a safety profile consistent with previously reported expansion data without severe neutropenia, peripheral neuropathy, or ocular toxicities; continued promising antitumor activity in ovarian cancer with 2/29 (7%) who achieved confirmed complete responses (CRs) and 8/29 (28%) who achieved confirmed partial responses (PRs) for an objective response rate (ORR) of 34%; and continued support for a NaPi2b biomarker-based patient selection strategy based on depth, time on study and quality of response. The Company has exceeded its recruitment goal of 40-45 patients in the ovarian cancer cohort of the XMT-1536 Phase 1 expansion study and will continue to enroll patients throughout the remainder of 2020.
- XMT-1536 granted Fast Track Designation underscoring the high unmet medical need in ovarian cancer. In
August 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for XMT-1536 for the treatment of patients with platinum-resistant high-grade serous ovarian cancer who have received up to three prior lines of systemic therapy or patients who have received four prior lines of systemic therapy regardless of platinum status.
- Mersana plans to host a virtual Analyst and Investor Day event to provide an update on the ovarian cancer cohort of the XMT-1536 Phase 1 expansion study and the path forward in ovarian cancer around year end. The Company anticipates that the year-end disclosure will include efficacy data from approximately 40-45 RECIST evaluable patients, safety data from approximately 65-70 patients, and approximately three months of patient follow up since the last data cutoff date of
August 18, 2020. In addition, the Company will review its plans for the registration-enabling study and outline its lifecycle management strategy for XMT-1536.
- New international sites added to support enrollment of the NSCLC adenocarcinoma patient cohort of the XMT-1536 Phase 1 expansion study. In the third quarter of 2020 the Company saw an increase in enrollment in the lung cancer cohort in parallel with the recent opening of international sites that had been delayed because of COVID-19. The Company will continue to recruit the expansion cohort and expects to discuss its data disclosure plans for the NSCLC adenocarcinoma patient cohort in early
- Phase 1 dose escalation study of XMT-1592, a Dolasynthen ADC targeting NaPi2b, proceeding to higher dose levels. XMT-1592 is the Company’s first clinical candidate created using its new Dolasynthen ADC platform. In preclinical studies, XMT-1592 showed four times greater efficacy in a patient-derived lung tumor model in comparison to XMT-1536, the Company’s Dolaflexin ADC that has already shown success when targeted to NaPi2b in the clinic. The Company continues to dose escalate and expects to discuss its data disclosure plans for XMT-1592 in early
Discovery & Platform Progress
- Mersana to present preclinical data supporting its first Immunosynthen development candidate in
November 2020. Immunosynthen, the Company’s novel STING-agonist ADC platform, has generated preclinical data across multiple targets and models showing complete regression of tumors in vivo after a single, well-tolerated dose, consistent with increased cytokine expression and immune cell infiltration within the tumor, and immune memory. The Company plans to present additional preclinical mechanistic data supporting the targeted dual activation of the STINGpathway in tumor cells and tumor-resident immune cells at the Society for Immunotherapy of Cancer(SITC) virtual meeting in November. In addition, the Company will host a webinar on November 16, 2020where it plans to review the therapeutic rationale for the development of STING-agonist ADCs including preclinical mechanistic data showing STINGactivation in both tumor cells and tumor-resident immune cells, the development and optimization of the Immunosynthen platform, and preclinical data supporting the Company’s Immunosynthen ADC pipeline as well as the Investigational New Drug timeline for the Company’s first development candidate.
- Mersana on track disclose its first-in-class ADC targeting B7-H4 development candidate and supporting data around year end. B7-H4 is expressed on both tumor cells and immunosuppressive tumor-associated macrophages (TAMs). This provides the potential for both a direct, cytotoxic antitumor effect as well as for additional payload delivery to the tumor microenvironment that can further contribute to immunogenic cell death, dendritic cell activation, and stimulation of an immune response consistent with the features of the Company’s unique DolaLock payload. IND-enabling studies are ongoing, and the Company plans to disclose its development candidate and supporting data at a virtual Analyst and Investor Day around year end.
- New addition to Executive Management Team. In
August 2020, the Company announced the appointment of Chuck Milleras Senior Vice President of Regulatory Affairs. Mr. Millerwas most recently Vice President of Regulatory Strategy and Labeling at TESARO, Inc before its acquisition by GSK. Prior to that, he worked as Executive Director of Regulatory Affairs at Cubist, before its acquisition by Merck.
- Refinancing of SVB Debt Agreement. In
August 2020, the Company entered into a second amendment of its debt agreement with Silicon Valley Bank. The amendment provides for an increased commitment amount and an extension of the interest-only payment period into 2022. The Company is no longer required to maintain a minimum liquidity ratio.
- Mersana will give a corporate presentation at the 29th Annual
Credit Suisse Virtual Healthcare Conferencescheduled for Thursday, November 11, 2020at 11:00 a.m. ET.
- Mersana will present preclinical data from its novel Immunosynthen STING-agonist ADC platform at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) as an on-demand poster display available from
November 11– 14, 2020.
- Mersana will host an Immunosynthen
STING-Agonist ADC Platform webinar on Monday, November 16, 2020at 8:00 a.m. ET.
Third Quarter 2020 Financial Results
Cash and cash equivalents as of
The Company expects that its cash and cash equivalents will enable it to fund its current operating plan commitments for more than two years. In addition, the Company has the option to draw additional funds through the debt financing agreement with
- Collaboration revenue for the third quarter of 2020 was immaterial, compared to
$0.8 millionfor the same period in 2019. The decrease in collaboration revenue was primarily a result of the completion of research services associated with a target included in the Merck KGaA agreement in the third quarter of 2019.
- Research and development expenses for the third quarter of 2020 were approximately
$16.5 million, compared to $13.7 millionfor the same period in 2019. The difference was primarily due to an increase in manufacturing activities for XMT-1536 and our discovery stage programs, an increase in XMT-1536 and XMT-1592 clinical expenses, increased headcount and an increased valuation of stock-based awards, an increase in consulting and professional fees and advancement of companion diagnostics development efforts for the NaPi2b biomarker. The increase was partially offset by a decrease in preclinical development and manufacturing expenses for XMT-1592 and discontinuation of XMT-1522.
- General and administrative expenses for the third quarter of 2020 were approximately
$5.9 million, compared to $4.4 millionduring the same period in 2019 primarily due to an increase in consulting and professional fees, an increase in valuation of stock-based awards, and an increase in facility-related costs as a result of the extension of the Company’s lease in March 2020.
- Net loss for the third quarter of 2020 was
$22.5 million, or $0.33per share, compared to a net loss of $16.8 million, or $0.35per share, for the same period in 2019. Weighted average common shares outstanding for the quarters ended September 30, 2020and September 30, 2019, were 68,419,192 and 47,833,607, respectively.
Conference Call Details
This press release contains “forward-looking” statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company’s business strategy and the design, progression and timing of its clinical trials. Forward-looking statements generally can be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continues,” “could,” “estimates,” “expects,” “goal,” “intends,” “may,” “on track,” “plans,” “possible,” “potential,” “predicts,” “projects,” “seeks,” “should,” “target,” “will,” “would” or similar expressions and the negatives of those terms. Forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. The Company’s operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Company’s results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials, that the development and testing of the Company’s product candidates and new platforms will take longer and/or cost more than planned, and that the identification of new product candidates will take longer than planned, as well as those listed in the Company’s Annual Report on Form 10-K filed on
Selected Condensed Consolidated Balance Sheet Data
|Cash, cash equivalents and marketable securities||$||270,936||$||99,790|
|Working capital (1)||253,864||77,256|
|Total stockholders' equity||253,308||78,318|
|(1) The Company defines working capital as current assets less current liabilities. See the Company's condensed consolidated financial statements for further detail regarding its current assets and current liabilities.|
Condensed Consolidated Statement of Operations
(in thousands, except share and per share data)
|Three months ended||Nine months ended|
|September 30,||September 30,||September 30,||September 30,|
|Research and development||16,546||13,701||44,179||42,610|
|General and administrative||5,881||4,436||15,988||13,072|
|Total operating expenses||22,427||18,137||60,167||55,682|
|Other income (expense), net||(73||)||501||147||1,639|
|Other comprehensive income (loss):|
|Unrealized gain (loss) on marketable securities||(2||)||17||(25||)||36|
|Net loss per share attributable to common stockholders — basic and diluted||$||(22,489||)||$||(16,792||)||$||(59,203||)||$||(11,962||)|
|Net loss per share attributable to common stockholders – basic and diluted||$||(0.33||)||$||(0.35||)||$||(1.00||)||$||(0.28||)|
|Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted||68,419,192||47,833,607||59,086,202||42,011,340|
Investor & Media Contact
Source: Mersana Therapeutics, Inc.